Modality
Radioligand
MOA
BTKi
Target
TIM-3
Pathway
Autophagy
EoE
Development Pipeline
Preclinical
Feb 2019
→ Nov 2028
PreclinicalCurrent
NCT03236838
1,086 pts·EoE
2019-12→2028-11·Completed
NCT08218990
1,963 pts·EoE
2019-02→2027-01·Completed
3,049 total pts1 indication
Phase 1
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (2)
2027-01-039mo awayInterim· EoE
2028-11-242.7y awayInterim· EoE
Trial Timeline
2019Q2Q3Q42020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q4
Preclinical
Complet…
Preclinical
Complet…
Catalysts
Interim
2027-01-03 · 9mo away
EoE
Interim
2028-11-24 · 2.7y away
EoE
Completed|StartCompletionToday
Trials (2)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT03236838 | Preclinical | EoE | Completed | 1086 | Biomarker |
| NCT08218990 | Preclinical | EoE | Completed | 1963 | BodyWt |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| AZN-8281 | AstraZeneca | Phase 1 | SHP2 | |
| BMY-3371 | Bristol-Myers Squibb | Phase 3 | WRN | |
| NVO-7872 | Novo Nordisk | NDA/BLA | B7-H3 | |
| NVO-6275 | Novo Nordisk | Phase 1 | SMN2 | |
| Zanumavacamten | GSK | Phase 2/3 | TROP-2 | |
| TAK-2403 | Takeda | Phase 2 | WEE1 | |
| Lisorapivir | Takeda | Preclinical | WRN | |
| REG-6699 | Regeneron | Phase 2/3 | TIM-3 | |
| Ivosotorasib | Vertex Pharma | Preclinical | CD38 | |
| MRN-8133 | Moderna | Phase 2 | PD-1 |